Nymox Pharmaceutical NX-1207 BPH Drug to be Presented at Orlando Meeting of American Urological Association

HASBROUCK HEIGHTS, N.J., Oct. 11, 2011 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that new clinical trial data concerning the safety and efficacy of the Company’s NX-1207 for benign prostatic hyperplasia (BPH) will be presented on November 4, 2011 at the Mid-Atlantic/New England Section of the American Urological Association Meeting in Orlando, FL. The presentation is authored by Neal Shore MD FACS, of Myrtle Beach, SC, Sheldon Freedman MD FACS, of Las Vegas, NV, Barton Wachs, MD FACS, of Long Beach, CA and Barrett Cowan, MD FACS, of Denver, CO.